Status:
UNKNOWN
Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women
Lead Sponsor:
Rabin Medical Center
Conditions:
Alopecia
Eligibility:
FEMALE
50+ years
Phase:
PHASE2
Brief Summary
The primary objective of this study is to assess the safety and efficacy of topical AS101 as treatment for Female Androgenetic Alopecia (FAGA) in menopause women.
Eligibility Criteria
Inclusion
- Women in menopause, over 50 years of age.
- Clinically diagnosed for AGA, according to Ludwig scale I-II.
Exclusion
- Women treated with chronic medications.
- Use of Minoxidil within 3 months prior to entering study.
- Women who have underwent hair transplantation.
- Use of drugs with androgenic or anti-androgenic effects.
- Any other type of hair loss.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00418249
Last Update
January 4 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tel Aviv, Israel